Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 325026, 8 pages
http://dx.doi.org/10.1155/2015/325026
Research Article

Effects of a Particular Heptapeptide on the IFN-α-Sensitive CML Cells

1Department of Biochemistry, School of Life Sciences and The State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan 410013, China
2Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
3Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Sichuan Medical University, Luzhou, Sichuan 646000, China
4Department of Biochemistry/Molecular Biology, Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131, USA

Received 24 June 2015; Revised 30 July 2015; Accepted 9 August 2015

Academic Editor: Massimo Breccia

Copyright © 2015 Fu-lan Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Quintás-Cardama and J. Cortes, “Molecular biology of bcr-abl1-positive chronic myeloid leukemia,” Blood, vol. 113, no. 8, pp. 1619–1630, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Chase, B. J. P. Huntly, and N. C. P. Cross, “Cytogenetics of chronic myeloid leukaemia,” Best Practice and Research: Clinical Haematology, vol. 14, no. 3, pp. 553–571, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. M. H. de Almeida, L. Fogliatto, and D. Couto, “Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia,” Revista Brasileira de Hematologia e Hemoterapia, vol. 36, no. 1, pp. 54–59, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Honda, T. Ushijima, K. Wakazono et al., “Acquired loss of p53 induces blastic transformation in p210(bcr)/abl)- expressing hematopoietic cells: a transgenic study for blast crisis of human CML,” Blood, vol. 95, no. 4, pp. 1144–1150, 2000. View at Google Scholar · View at Scopus
  5. A. Hai, N. A. Kizilbash, S. H. H Zaidi, J. Alruwaili, and K. Shahzad, “Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia,” Bioinformation, vol. 10, no. 3, pp. 108–114, 2014. View at Publisher · View at Google Scholar
  6. N. Chatain, P. Ziegler, D. Fahrenkamp et al., “Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells,” Oncogene, vol. 32, no. 31, pp. 3587–3597, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Notari, P. Neviani, R. Santhanam et al., “A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation,” Blood, vol. 107, no. 6, pp. 2507–2516, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Latagliata, A. Romano, M. Mancini et al., “Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response,” Leukemia & Lymphoma, 2015. View at Publisher · View at Google Scholar
  9. M. Ilander, A. Kreutzman, and S. Mustjoki, “IFN-α induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia,” OncoImmunology, vol. 3, no. 4, Article ID e28781, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Simonsson, H. Hjorth-Hansen, O. W. Bjerrum, and K. Porkka, “Interferon alpha for treatment of chronic myeloid leukemia,” Current Drug Targets, vol. 12, no. 3, pp. 420–428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Bekisz, S. Baron, C. Balinsky, A. Morrow, and K. C. Zoon, “Antiproliferative properties of type I and type II interferon,” Pharmaceuticals, vol. 3, no. 4, pp. 994–1015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Bonifazi, A. de Vivo, G. Rosti et al., “Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders,” Blood, vol. 98, no. 10, pp. 3074–3081, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Feng and B. J. Barnes, “Bioinformatics analysis of the factors controlling type I IFN gene expression in autoimmune disease and virus-induced immunity,” Frontiers in Immunology, vol. 4, article 291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. L. C. Platanias, “Mechanisms of type-I- and type-II-interferon-mediated signalling,” Nature Reviews Immunology, vol. 5, no. 5, pp. 375–386, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. I. M. Grumbach, I. A. Mayer, S. Uddin et al., “Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells,” British Journal of Haematology, vol. 112, no. 2, pp. 327–336, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Yamauchi, I. Sakai, H. Narumi, K. Takeuchi, S. Soga, and S. Fujita, “Development of interferon-alpha resistant subline from human chronic myelogenous leukemia cell line KT-1,” Internal Medicine, vol. 40, no. 7, pp. 607–612, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. H. J. Khoury and D. L. Bixby, “Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy,” Leukemia & Lymphoma, vol. 56, no. 3, pp. 568–576, 2015. View at Publisher · View at Google Scholar
  18. M. Dimou and P. Panayiotidis, “Tyrosine kinase inhibitors and interferon,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 6, no. 1, Article ID e2014006, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-J. Kiladjian, R. A. Mesa, and R. Hoffman, “The renaissance of interferon therapy for the treatment of myeloid malignancies,” Blood, vol. 117, no. 18, pp. 4706–4715, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. W. Deininger, and B. J. Druker, “Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity,” The Journal of Clinical Investigation, vol. 121, no. 1, pp. 396–409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Potenza, F. Volzone, G. Riva et al., “Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation,” British Journal of Haematology, vol. 146, no. 2, pp. 227–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Palandri, F. Castagnetti, I. Iacobucci et al., “The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 philadelphia-positive chronic myeloid leukemia patients in early chronic phase,” Haematologica, vol. 95, no. 8, pp. 1415–1419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. M. El Eit, A. N. Iskandarani, J. L. Saliba et al., “Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha,” International Journal of Cancer, vol. 134, no. 4, pp. 988–996, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Talpaz, J. Mercer, and R. Hehlmann, “The interferon-alpha revival in CML,” Annals of Hematology, vol. 94, supplement 2, pp. S195–S207, 2015. View at Publisher · View at Google Scholar
  25. A. Burchert, S. Saussele, E. Eigendorff et al., “Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia,” Leukemia, vol. 29, no. 6, pp. 1331–1335, 2015. View at Publisher · View at Google Scholar
  26. S. Katagiri, T. Tauchi, T. Umezu et al., “Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib,” Rinsho Ketsueki, vol. 56, no. 2, pp. 216–219, 2015. View at Publisher · View at Google Scholar
  27. J. Liu, H.-C. Chen, Z.-Z. Rao et al., “Identification of heptapeptides interacting with IFN-α-sensitive CML cells,” Expert Opinion on Investigational Drugs, vol. 20, no. 12, pp. 1583–1589, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. N. L. Nicolson, M. Talpaz, and G. L. Nicolson, “Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia,” Gene, vol. 169, no. 2, pp. 173–178, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Glowacki, E. Synowiec, and J. Blasiak, “The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors,” International Journal of Molecular Sciences, vol. 14, no. 8, pp. 16348–16364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Schreiber and M. Peter, “Substrate recognition in selective autophagy and the ubiquitin-proteasome system,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1843, no. 1, pp. 163–181, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Yang and X. Yu, “Regulation of apoptosis: the ubiquitous way,” The FASEB Journal, vol. 17, no. 8, pp. 790–799, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Zheng, J. Qian, B. Varghese, D. P. Baker, and S. Fuchs, “Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2,” Molecular and Cellular Biology, vol. 31, no. 4, pp. 710–720, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Yu and G. S. Hayward, “The ubiquitin E3 ligase RAUL negatively regulates type I interferon through ubiquitination of the transcription factors IRF7 and IRF3,” Immunity, vol. 33, no. 6, pp. 863–877, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. X.-X. Wan, H.-C. Chen, M. A. Khan et al., “ISG15 inhibits IFN-α-resistant liver cancer cell growth,” BioMed Research International, vol. 2013, Article ID 570909, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Nakasato, K. Ikeda, T. Urano, K. Horie-Inoue, S. Takeda, and S. Inoue, “A ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with ISG15,” Biochemical and Biophysical Research Communications, vol. 351, no. 2, pp. 540–546, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Eibl, E. Greiter, K. Grünewald et al., “Expression of c-fos correlates with IFN-alpha responsiveness in Philadelphia chromosome positive chronic myelogenous leukemia,” Cytokines and Molecular Therapy, vol. 1, no. 1, pp. 29–38, 1995. View at Google Scholar · View at Scopus
  37. F. Pane, I. Mostarda, C. Selleri et al., “BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients,” Blood, vol. 94, no. 7, pp. 2200–2207, 1999. View at Google Scholar · View at Scopus